Beyond the Hospital Walls: Thriving in Value-Based Care
[Sponsored] Steve Holt, Vice President of Government Affairs with PointClickCare, discussed what hospitals and ACOs…
Beyond the Hospital Walls: Thriving in Value-Based Care
[Sponsored] Steve Holt, Vice President of Government Affairs with PointClickCare, discussed what hospitals and ACOs need to succeed with alternative payment model programs such as AHEAD, TEAM, and ACO REACH The post Beyond the Hospital Walls: Thriving in Value-Based Care appeared first on MedCity News.
A Preview of Healthcare Startups Competing in the INVEST Digital Health Pitch Perfect Contest
Six healthcare startups using AI to address a variety of healthcare challenges will vie for the top prize at the conference at Pegasus Park in Dallas on September 18. Register today! The post A Preview of Healthcare Startups Competing in the INVEST Digital Health Pitch Perfect Contest appeared first on MedCity News.
Do Pediatricians Recommend Vaccines To Make a Profit? There’s Not Much Money in It
It makes sense to approach some marketing efforts with skepticism. Scams, deepfakes, and deceptive social media posts are common, with people you don’t know seeking to profit from your behavior. But should people extend this same skepticism to pediatricians who advise vaccines for children? Health and Human Services Secretary Robert F. Kennedy Jr. said financial…
At CDC, Worries Mount That Agency Has Taken Anti-Science Turn
Public health and access to lifesaving vaccines are on the line in a high-stakes leadership battle at the Centers for Disease Control and Prevention. Health and Human Services Secretary Robert F. Kennedy Jr.’s push to fire CDC director Susan Monarez is more than an administrative shake-up. The firing marks a major offensive by Kennedy to…
Changes at NIH Give Political Appointees Greater Power To Fund or Block Research
The Trump administration has given notice that political appointees, rather than scientists, will ultimately decide who gets grant money from the world’s largest biomedical research funder — the federal government’s National Institutes of Health. In an Aug. 7 executive order, President Donald Trump announced that political officers would have the power to summarily cancel any…
Formulary restrictions and health outcomes: A case study in multiple sclerosis
How does formulary restrictions impact health outcomes for patients with multiple sclerosis (MS)? To answer this question, Blaylock, Van Nuys and Joyce (2025) use data 100% Medicare claims data from 2018-2022 covering patients with both prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs). Individuals were categorized as above vs. below average formulary…
Cuando los pacientes quedan atrapados en medio de las peleas entre aseguradoras y hospitales
Amy Frank dijo que pasó 17 horas al teléfono durante casi tres semanas, rebotando entre su aseguradora y el sistema hospitalario local, para asegurarse de que el plan de salud cubriera la atención que su esposo necesitaba después de una cirugía. Muchas de sus llamadas no pasaron de la música en espera. Cuando lograba comunicarse,…
CMS: ACOs in Shared Savings Program Saved Medicare $2.4B in 2024
Out of the 476 ACOs that participated in the Medicare Shared Savings Program in 2024, 75% earned $4.1 billion in performance payments, CMS reported. The post CMS: ACOs in Shared Savings Program Saved Medicare $2.4B in 2024 appeared first on MedCity News.
Owen Tripp, Included Health, talks AI
“So far AI in health care is being used to drive existing profits on workflows and increase revenue per event that patients in the end have to pay for. That’s not a win for anyone long term!” Included Health’s CEO Owen Tripp dives into the present and future use of AI, LLMs, patient self-triage and…
Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy
Novartis, which already has experience with RNA interference therapies, is now turning to this modality as a potential way to treat Parkinson’s disease. The pharmaceutical giant is licensing rights to an Arrowhead Pharmaceuticals RNAi therapy designed to inhibit production of alpha synuclein, a protein associated with Parkinson’s progression. The post Novartis Tries Again in Parkinson’s,…
